Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| Actinium Pharmaceuticals | Iomab-ACT | targeted conditioning prior to treatment with MSK's CD19 targeted CAR T-cell 19-28z | initiation of phase 1 trial |
| Pfizer | PF-07321332 | treatment of COVID-19 | initiation of phase 1 trial |
| Angion Biomedica | ANG-3777 | reduction of severity and progression of acute lung injury in patients with COVID-19-associated pneumonia who are at high risk of progressing to acute respiratory distress syndrome | completion of patient enrollment in phase 2 trial |
| BioAge Labs | BGE-175 | COVID-19 patients age 60 or older | initiation of phase 2 trial |
| Clover Biopharm Dynavax |
Clover's COVID-19 vaccine adjuvanted with Dynavax's CpG 1018 plus alum | COVID-19 vaccine | first patients dosed in phase 2/3 trial |
| NeuroRx | inhaled Zyesami | moderate and severe COVID-19 | first patient dosed in phase 2/3 trial |
| Beckman Coulter | SARS-CoV-2 IgG II antibody test | measurement of antibodies in response to a previous SARS-CoV-2 infection | Emergency Use Authorization (EUA) granted by the FDA |
| LetsGetChecked | Coronavirus (COVID-19) home collection test | COVID-19 testing at home | EUA granted by the FDA |
| Other Trials and Actions | |||
| Cybrexa Therapeutics | CBX-12 (alphalex-exatecan) | solid tumors | IND approved by the FDA |
| JAR of Hope | JAR914 | Duchenne muscular dystrophy | IND approved by the FDA |
| PEP-Therapy | PEP-010 | recurrent and/or metastatic solid tumors | approval from the French National Agency for Medicines and Health Products to begin clinical trials |
| Anokion | ANK-700 | relapsing remitting multiple sclerosis | first patients dosed in phase 1 trial |
| CARISMA Therapeutics | CT-0508 | recurrent or metastatic HER2-overexpressing solid tumors in patients whose cancers do not have any approved HER2-targeted therapies or who do not respond to treatment | first patient dosed in phase 1 trial |
| Diffusion Pharmaceuticals | trans sodium crocetinate | hypoxia, lung disease | completion of phase 1 trials |
| Harbour Biomed | HBM4003 | advanced melanoma and other solid tumors | initiation of phase 1 trial in China |
| Nascent Biotech | pritumumab | brain cancer | initiation of phase 1 trial |
| Precigen | PRGN-2012 | recurrent respiratory papillomatosis | first patient dosed in phase 1 trial |
| Terns Pharmaceuticals | TERN-501 | nonalcoholic steatohepatitis and other liver diseases | initiation of phase 1 trial |
| vTv Therapeutics | TTP399 | to reduce risk of diabetic ketoacidosis in patients with type 1 diabetes | initiation of phase 1 trial |
| Rapt Therapeutics | RPT193 | moderate-to-severe atopic dermatitis | patient enrollment complete in phase 1b trial |
| Actinium Pharmaceuticals | Actimab-A venetoclax | relapsed or refractory acute myeloid leukemia | completion of enrollment of second dose cohort |
| Hutchison China MediTech BeiGene |
surufatinib in combination with BeiGene’s tislelizumab | advanced solid tumors | initiation of phase 1b/2 trial |
| NeoImmuneTech | NT-I7 (efineptakin alfa) in combination with Keytruda (pembrolizumab) | relapsed/refractory advanced solid tumors | first patient dosed in phase 2a portion of phase 1b/2a trial |
| Arcutis Pharmaceuticals | ARQ-252 | vitiligo | first patient enrolled in phase 2a trial |
| AzurRx BioPharma | MS1819 in combination with pancreatic enzyme replacement therapy | cystic fibrosis | patient enrollment complete in phase 2 trial |
| Otonomy | OTO-313 | unilateral tinnitus | initiation of phase 2 trial |
| Visus Therapeutics | Brimochol topical ophthalmic solution | presbyopia | initiation of phase 2 trial |
| Akero Therapeutics | efruxifermin | F2/F3 nonalcoholic steatohepatitis | first patient randomized in phase 2b trial |
| DARÉ Bioscience | sildenafil cream, 3.6% | female sexual arousal disorder | initiation of a phase 2b trial |
| Oramed | oral insulin capsule, ORMD-0801 | type 2 diabetes | initiation of phase 3 trial |
| Celularity | CYNK-001 | recurrent glioblastoma multiforme | Fast-Track designation granted by the FDA |
| Janssen | Ponvory (ponesimod) | relapsing forms of multiple sclerosis | approved by the FDA |
| Kiniksa Pharmaceuticals | Arcalyst (rilonacept) | recurrent pericarditis | approved by the FDA |
| Merck | Keytruda (pembrolizumab) | first-line treatment of esophageal and GEJ carcinoma, regardless of histology or PD-L1 expression | approved by the FDA for expanded indication |
| Immunicom | Immunopheresis LW-02 blood-filtering column | advanced refractory triple negative breast cancer | approved in Europe |
| Insmed | Arikayce (amikacin liposome inhalation suspension) | nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC) in patients who did not sufficiently respond to prior treatment with a multidrug regimen | approved in Japan |
| Incyte | Pemazyre (pemigatinib) | FGFR2+ unresectable biliary tract cancer | approved in Japan |
| Life Spine | PROLIFT Wedge Expandable Spacer System | surgical treatment of spinal disorders | approved by the FDA |
Upcoming Events
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May
